Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.

Raimundo S, Toscano C, Klein K, Fischer J, Griese EU, Eichelbaum M, Schwab M, Zanger UM.

Clin Pharmacol Ther. 2004 Aug;76(2):128-38.

PMID:
15289790
2.

Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.

Toscano C, Klein K, Blievernicht J, Schaeffeler E, Saussele T, Raimundo S, Eichelbaum M, Schwab M, Zanger UM.

Pharmacogenet Genomics. 2006 Oct;16(10):755-66.

PMID:
17001295
3.

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

Sachse C, Brockmöller J, Bauer S, Roots I.

Am J Hum Genet. 1997 Feb;60(2):284-95.

4.

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.

Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K, Stüven T, Eichelbaum M.

Pharmacogenetics. 1998 Feb;8(1):15-26.

PMID:
9511177
5.

Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.

Gaedigk A, Bradford LD, Marcucci KA, Leeder JS.

Clin Pharmacol Ther. 2002 Jul;72(1):76-89.

PMID:
12152006
6.

Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.

Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M.

Pharmacogenetics. 1999 Dec;9(6):715-23.

PMID:
10634134
7.

The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements.

Gaedigk A, Coetsee C.

Eur J Clin Pharmacol. 2008 May;64(5):465-75. doi: 10.1007/s00228-007-0445-7. Epub 2008 Jan 17.

PMID:
18202841
8.

Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.

Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS.

Pharmacogenetics. 1999 Dec;9(6):669-82.

PMID:
10634130
9.

Identification of CYP2D6 impaired functional alleles in Mexican Americans.

Luo HR, Gaedigk A, Aloumanis V, Wan YJ.

Eur J Clin Pharmacol. 2005 Dec;61(11):797-802. Epub 2005 Nov 8.

PMID:
16283274
10.

A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype.

Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T, Kinoshita M, Sato K, Gonzalez FJ, Kamataki T.

Pharmacogenetics. 1996 Oct;6(5):395-401.

PMID:
8946471
11.

Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians.

Legrand-Andréoletti M, Stücker I, Marez D, Galais P, Cosme J, Sabbagh N, Spire C, Cenée S, Lafitte JJ, Beaune P, Broly F.

Pharmacogenetics. 1998 Feb;8(1):7-14.

PMID:
9511176
12.

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.

Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM.

Pharmacogenetics. 2000 Oct;10(7):577-81.

PMID:
11037799
13.
14.

CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.

Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK.

Pharmacogenetics. 1998 Dec;8(6):529-41.

PMID:
9918137
15.

CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.

López M, Guerrero J, Jung-Cook H, Alonso ME.

Eur J Clin Pharmacol. 2005 Nov;61(10):749-54. Epub 2005 Oct 26.

PMID:
16249913
16.

Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.

Steen VM, Andreassen OA, Daly AK, Tefre T, Børresen AL, Idle JR, Gulbrandsen AK.

Pharmacogenetics. 1995 Aug;5(4):215-23.

PMID:
8528268
17.

Rapid detection of common cytochrome P450 2D6 alleles in Caucasians.

Roberts RL, Kennedy MA.

Clin Chim Acta. 2006 Apr;366(1-2):348-51. Epub 2005 Dec 20.

PMID:
16364273
18.

Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.

Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, Kondo I, Gonzalez FJ.

Pharmacogenetics. 1993 Oct;3(5):256-63.

PMID:
8287064
19.

A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.

Toscano C, Raimundo S, Klein K, Eichelbaum M, Schwab M, Zanger UM.

Pharmacogenet Genomics. 2006 Oct;16(10):767-70.

PMID:
17001296
20.

Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.

Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F.

Pharmacogenetics. 1997 Jun;7(3):193-202.

PMID:
9241659

Supplemental Content

Support Center